Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma gets Nasdaq notice for below-minimum market value; 180 days to comply

Negative Impact 4 of 5 legal/regulatory Written later

Estrella Immunopharma received a Nasdaq notice on September 1, 2026, stating its market value of listed securities fell below the $35 million minimum for 30 consecutive business days. The company has until March 1, 2027 to regain compliance, and the stock continues to trade on Nasdaq for now, but failure to comply could lead to delisting proceedings.

Key points

  • Nasdaq notice dated September 1, 2026 cites market value of listed securities below $35,000,000 for 30 consecutive business days, July 21 through August 31, 2026
  • Company does not meet Nasdaq's alternative standards for stockholders' equity of at least $2,500,000 or net income of at least $500,000
  • Compliance deadline is March 1, 2027; regaining compliance requires closing at $35,000,000 or more for at least ten consecutive business days
  • Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA

The filing

CompanyEstrella Immunopharma, Inc. (ESLA)
Form8-K, current report
Filed with the SECSep 8, 2026, 5:25 PM ET
Accession number0001213900-26-098123

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.